Evaluation of the flare levels and central macular thickness after intravitreal injection of ranibizumab, aflibercept or triamcinolone acetonide in diabetic macular edema patients

Evaluation of the flare levels and central macular thickness after intravitreal injection of ranibizumab, aflibercept or triamcinolone acetonide in diabetic macular edema patients - Flare levels and central macular thickness after intravitreal injection in diabetic macular edema

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000025769

Enrollment

100

Registered

2017-01-20

Start date

2017-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic macular edema

Interventions

ranibizumab aflibercept triamcinolone acetonide

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: more than 20 years old Patients diagnosed as type 2 diabetic mellitus with diabetic macular edema (more than 350 um in central retinal thickness) Patients gave informed consent

Exclusion criteria

Exclusion criteria: Unconteroled hypertension and renal diseases Allergy for drugs plegnant women

Design outcomes

Primary

Measure	Time frame
Flare intensity Central macular thickness	—

Countries

Japan

Contacts

Public ContactYoshihiro Takamura

University of Fukui Ophthalmology

ytakamura@hotmail.com+81-776-61-8403

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026